PANVAC
AXP000179.1 · Cancer vaccine
- Platform
- poxvirus prime-boost (vaccinia prime, fowlpox boost)
- Targets
- CEACAM5; MUC1
- Originator
- Therion Biologics
Names
| Name | Type | Source |
|---|---|---|
| PANVAC ambiguous | preferred name, code | curator, curator |
| falimarev | INN | ncit |
| inalimarev | INN | ncit |
| PANVAC-F | code | ncit |
| PANVAC-V | code | ncit |
| PANVAC-VF | code | ctgov |
| TBC-PAN-003 | code | ctgov |
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- PANVAC-V (vaccinia) prime; PANVAC-F (fowlpox) boost
- Replication
- replicating
- Modifications
- CEA(D609), MUC1(L93) and TRICOM cassettes; replication-competent vaccinia prime, non-replicating fowlpox boost
- Transgenes
- CEACAM5, MUC1, CD80, ICAM1, CD58
- Route
- subcutaneous
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (6)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT02015104 | Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG | Completed | Phase 2 | 2013-12-18 | 2018-09-18 | 32 | Bladder Cancer |
| NCT00669734 | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery | Active not recruiting | Phase 1 | 2010-02-01 | 2021-09-02 | 18 | Locally Advanced Pancreatic Adenocarcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7 |
| NCT00179309 | Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer | Completed | Phase 2 | 2005-09 | 2013-02 | 48 | Breast Cancer |
| NCT00103142 | Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer | Completed | Phase 2 | 2005-02 | 2009-06 | 74 | Colorectal Cancer; Metastatic Cancer |
| NCT00088413 | PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer | Completed | Phase 1/2 | 2004-07-21 | 2018-04-01 | 51 | Adenocarcinoma; Breast Cancer; Colorectal Cancer; Ovarian Cancer |
| NCT00088660 | PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen | Unknown | Phase 3 | 2004-06 | 250 | Pancreatic Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40443562 | Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research. | The breast journal | 2025 | cited by trial NCT00088413 |
| PMID 40781051 | Bacillus Calmette-Guérin (BCG) in combination with PANVAC™ vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancer. | Urologic oncology | 2025 | name in title: PANVAC |
| PMID 26291768 | Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. | JAMA oncology | 2015 | cited by trial NCT00179309 |
| PMID 23657083 | A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. | Annals of surgery | 2013 | cited by trial NCT00103142 |
| PMID 22068656 | A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2011 | cited by trial NCT00088413 |
| PMID 18483372 | Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2008 | cited by trial NCT00088413 |
| PMID 18039393 | Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. | Journal of translational medicine | 2007 | name in abstract: PANVAC-V |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39453092 | Partial Sequence Analysis of Commercial Peste des Petits Ruminants Vaccines Produced in Africa. | Veterinary sciences | 2024 | name in abstract: PANVAC |
| PMID 37684280 | The evaluation of five serological assays in determining seroconversion to peste des petits ruminants virus in typical and atypical hosts. | Scientific reports | 2023 | name in abstract: PANVAC |
| PMID 35158964 | From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC). | Cancers | 2022 | name in abstract: PANVAC |
| PMID 30626434 | Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. | Journal for immunotherapy of cancer | 2019 | name in abstract: PANVAC |
| PMID 31110074 | A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2019 | name in abstract: PANVAC |
| PMID 31131993 | Detection and molecular characterization of Peste des Petits Ruminants virus from outbreaks in Burundi, December 2017-January 2018. | Transboundary and emerging diseases | 2019 | name in abstract: PANVAC |
| PMID 31635322 | Development and Evaluation of Epitope-Blocking ELISA for Detection of Antibodies against Contagious Caprine Pleuropneumonia in Goat Sera. | Veterinary sciences | 2019 | name in abstract: PANVAC |
| PMID 29520689 | Development and validation of an epitope-blocking ELISA using an anti-haemagglutinin monoclonal antibody for specific detection of antibodies in sheep and goat sera directed against peste des petits ruminants virus. | Archives of virology | 2018 | name in abstract: PANVAC |
| PMID 27485137 | Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. | Cancer immunology research | 2016 | name in abstract: PANVAC |
| PMID 22380820 | Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm. | Expert review of vaccines | 2012 | name in title: PANVAC |
| PMID 22595052 | Clinical evaluation of TRICOM vector therapeutic cancer vaccines. | Seminars in oncology | 2012 | name in abstract: PANVAC |
| PMID 22892452 | Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC). | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2012 | name in title: PANVAC |
| PMID 19907722 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2009 | name in abstract: inalimarev |
| PMID 19088949 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2008 | name in abstract: inalimarev |
| PMID 17373905 | PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. | Expert opinion on biological therapy | 2007 | name in title: PANVAC-VF |
| PMID 16451103 | Development of the PANVAC-VF vaccine for pancreatic cancer. | Expert review of vaccines | 2006 | name in title: PANVAC-VF |
| PMID 16512998 | A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma. | Clinical colorectal cancer | 2006 | name in title: PANVAC |
| PMID 16800982 | A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). | Clinical breast cancer | 2006 | name in title: PANVAC-V |
| PMID 8593393 | Contagious bovine pleuropneumonia vaccines: the need for improvements. | Revue scientifique et technique (International Office of Epizootics) | 1995 | name in abstract: PANVAC |
| PMID 8639954 | Regulatory framework and requirements for managing risks associated with veterinary biological products in Africa: present systems and future needs. | Revue scientifique et technique (International Office of Epizootics) | 1995 | name in abstract: PANVAC |
| PMID 8639956 | The role of international and regional organisations in the regulation of veterinary biologicals. | Revue scientifique et technique (International Office of Epizootics) | 1995 | name in abstract: PANVAC |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| ZIABC010598 | Human Immune Responses to Tumor Antigens for Cancer Immunotherapy | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2012–2025 | name in abstract: PANVAC |
| ZIABC010666 | Cancer Immunotherapy | DIVISION OF BASIC SCIENCES - NCI | GULLEY, JAMES L. | 2009–2025 | name in abstract: PANVAC-V |
| ZIABC010425 | Strategies for Cancer Immunotherapy Clinical Trials | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2009–2023 | name in abstract: PANVAC-V |
| ZIABC010945 | Clinical trials employing cancer vaccine combination therapies | DIVISION OF BASIC SCIENCES - NCI | GULLEY, JAMES L. | 2009–2022 | name in abstract: PANVAC-V |
| ZIABC011547 | Cancer Immunotherapy Clinical Trials | DIVISION OF BASIC SCIENCES - NCI | STRAUSS, JULIUS | 2014–2022 | name in abstract: PANVAC |
| ZICBC011044 | Tissue Processing-Sequencing Facility | DIVISION OF BASIC SCIENCES - NCI | VOCKE, CATHY D | 2015–2022 | name in abstract: PANVAC |
| ZIABC011865 | Breast and Other Carcinoma Clinical Trials Using Immunotherapies | DIVISION OF BASIC SCIENCES - NCI | GATTI-MAYS, MARGARET | 2019–2020 | name in abstract: PANVAC |
| ZIABC011528 | A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus | DIVISION OF BASIC SCIENCES - NCI | AGARWAL, PIYUSH | 2013–2019 | name in abstract: PANVAC |
| ZIABC010972 | Identification of human tumor-associated antigens | DIVISION OF BASIC SCIENCES - NCI | TSANG, KWONG YOK | 2009–2016 | name in abstract: PANVAC-V |
| ZIABC011281 | Combination therapies involving novel cancer vaccines | DIVISION OF BASIC SCIENCES - NCI | MADAN, RAVI | 2010–2013 | name in abstract: PANVAC-V |
| ZIABC011280 | Cancer Therapy Trials using novel vaccine platforms | DIVISION OF BASIC SCIENCES - NCI | MADAN, RAVI | 2010–2012 | name in abstract: PANVAC-V |
| M01RR001070 | CLINICAL TRIAL: ACTIVE IMMUNOTHERAPY AFTER RESECTION OF HEPATIC METASTASES OF CO | MEDICAL UNIVERSITY OF SOUTH CAROLINA | COLE, DAVID J | 2008–2008 | name in abstract: PANVAC-V |
| Z01BC010425 | Analysis of Human Immune Reponses in Cancer Vaccine Clinical Trials | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2006–2008 | name in abstract: PANVAC-V |
| Z01BC010666 | Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines | DIVISION OF BASIC SCIENCES - NCI | GULLEY, JAMES L. | 2006–2008 | name in abstract: PANVAC-VF |
| Z01BC010662 | Vaccine Clinical Trials | DIVISION OF BASIC SCIENCES - NCI | ARLEN, PHILIP M | 2006–2007 | name in abstract: PANVAC-VF |
| Z01SC010365 | Optimizing the Graft-Versus-Tumor Effect in Allogeneic H | DIVISION OF CLINICAL SCIENCES - NCI | BISHOP, MICHAEL R | 2005–2006 | name in abstract: PANVAC |
Notes
PANVAC-V (inalimarev, NCIt C29317) vaccinia prime plus PANVAC-F (falimarev, NCIt C29316) fowlpox boosts, both encoding CEA, MUC-1 and TRICOM; one program (one prime-boost product), so ncit left empty rather than pick one component concept. Phase 3 NCT00088660 (TBC-PAN-003) in metastatic pancreatic cancer after gemcitabine, sponsored by Therion Biologics; Therion wound down in 2006. NCIt lists 'PANVAC' also as a synonym of CV301 (AXP000143), which is the later MVA-BN-based remake: that alias is marked ambiguous.
How to cite
PANVAC (AXP000179.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000179.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.